<p>HCA Healthcare（紐約證券交易所代碼：HCA - 獲取免費報告）在週二發佈的報告中，摩根大通將其目標價從 535.00 美元下調至 490.00 美元，MarketScreener 報道。該券商目前對該股票給予 “中性” 評級。摩根大通的目標價意味着該股票相較於之前的收盤價有 20.76% 的潛在上漲空間。</p>
<p>獲取 <strong>HCA Healthcare</strong> 的提醒：</p>
<ul>
<li>美國老齡化可能使 HCA Healthcare 成為長期贏家</li>
</ul>
<p>其他一些研究公司也對 HCA 發表了看法。Cantor Fitzgerald 在 3 月 4 日的研究報告中重申了對 HCA Healthcare 股票的 “增持” 評級。高盛集團在 1 月 28 日的報告中將 HCA Healthcare 的目標價從 520.00 美元上調至 558.00 美元，並給予該公司 “買入” 評級。Leerink Partners 在 4 月 27 日的研究報告中將 HCA Healthcare 的目標價從 573.00 美元下調至 500.00 美元，並對該公司給予 “跑贏大盤” 評級。華爾街 Zen 在 5 月 2 日的研究報告中將 HCA Healthcare 的評級從 “買入” 下調至 “持有”。最後，KeyCorp 在 4 月 27 日的報告中將 HCA Healthcare 的目標價從 550.00 美元下調至 510.00 美元，並對該股票給予 “增持” 評級。十六位研究分析師對該股票給予 “買入” 評級，七位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 515.77 美元。</p>
<p><strong>查看我們關於 HCA 的最新報告</strong></p>
<h2>HCA Healthcare 股票表現</h2>
<ul>
<li>該 ETF 證明醫療保健反彈是真實的</li>
</ul>
<p>週二，紐約證券交易所 HCA 的交易價格下跌 17.02 美元，達到 405.77 美元。該公司的股票交易量為 245,089 股，而其平均交易量為 1,122,558 股。HCA Healthcare 的十二個月低點為 330.00 美元，十二個月高點為 556.52 美元。該公司的市值為 900.2 億美元，市盈率為 14.04，市盈率/增長比率為 1.34，貝塔值為 1.18。該公司的 50 日移動平均價格為 476.49 美元，200 日移動平均價格為 485.66 美元。</p>
<p>HCA Healthcare（紐約證券交易所代碼：HCA - 獲取免費報告）最近在 4 月 24 日發佈了季度財報。該公司報告每股收益（EPS）為 7.15 美元，低於共識預期的 7.19 美元（差額為 0.04 美元）。該公司在本季度的收入為 191.1 億美元，而分析師預期為 190.9 億美元。HCA Healthcare 的淨利潤率為 8.89%，股本回報率為負 295.93%。該公司的收入同比增長 4.3%。去年同期，該公司每股收益為 6.45 美元。HCA Healthcare 已將其 2026 財年的指導目標設定為 29.100-31.500 美元每股收益。作為一個整體，賣方分析師預測 HCA Healthcare 在當前財年將發佈 30.07 美元每股收益。</p>
<h2>HCA Healthcare 的內部買賣</h2>
<ul>
<li>MarketBeat 週報 – 07/28 - 08/01</li>
</ul>
<p>在相關消息中，執行副總裁 Michael R. Mcalevey 在 2 月 18 日的交易中出售了 1,694 股公司的股票。該股票以平均價格 533.37 美元出售，總價值為 903,528.78 美元。出售後，該執行副總裁持有 8,853 股公司的股票，價值約為 4,721,924.61 美元。這代表其持股減少了 16.06%。該交易已在證券交易委員會的備案中披露，可以通過此鏈接訪問。公司內部人士目前持有 1.50% 的股票。</p>
<h2>HCA Healthcare 的機構交易</h2>
<p>大型投資者最近對該股票的持倉進行了調整。國家養老服務在第三季度將其在 HCA Healthcare 的股份增加了 2.9%。國家養老服務目前持有 626,585 股公司股票，價值為 267,051,000 美元，此前在上個季度購買了 17,531 股。Savant Capital LLC 在第三季度將其在 HCA Healthcare 的股份增加了 37.7%。Savant Capital LLC 目前持有 4,548 股公司股票，價值為 1,938,000 美元，此前在上個季度增加了 1,246 股。Sector Gamma AS 在第三季度將其在 HCA Healthcare 的持倉增加了 36.0%。Sector Gamma AS 目前持有 10,883 股公司股票，價值為 4,638,000 美元，此前在上個季度增加了 2,883 股。Nordea Investment Management AB 在第四季度將其在 HCA Healthcare 的持倉增加了 11.2%。Nordea Investment Management AB 目前持有 1,084,590 股公司股票，價值為 507,393,000 美元，此前在上個季度購買了 108,849 股。最後，AlphaQuest LLC 在第三季度將其在 HCA Healthcare 的持倉增加了 2,855.2%。AlphaQuest LLC 目前持有 5,999 股公司股票，價值為 2,557,000 美元，此前在上個季度增加了 5,796 股。機構投資者和對沖基金持有該公司 62.73% 的股票。</p>
<h2>關於 HCA Healthcare</h2>
<p>（獲取免費報告）</p>
<p>HCA Healthcare 是一家以盈利為目的的醫療設施運營商，總部位於田納西州納什維爾。該公司成立於 1968 年，擁有並運營一系列醫院和相關醫療設施，並通過有機擴展和收購成長為大型住院和門診服務提供商。</p>
<p>該公司的核心業務包括急性護理醫院、獨立外科和急救中心以及門診診所的運營。HCA 的服務涵蓋住院護理、外科服務、急救醫學、診斷影像和實驗室檢測，以及各種門診和流動護理服務。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比 HCA Healthcare 更好</li>
<li>重塑人工智能：NextEra Energy 引發了一場巨型合併</li>
<li>切換開關：福特會是下一個大能源股票嗎？</li>
<li>納米核能的新交易是否提升了前景？</li>
<li>3 只內部人士在 2026 年買入的股息股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhDQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhDQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 HCA Healthcare 嗎？</h2>
<p>在考慮 HCA Healthcare 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 HCA Healthcare 並不在名單上。</p>
<p>雖然 HCA Healthcare 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HCA控股

標普全球醫療股指數 ETF - iShares

美國醫療保健供應商 ETF - iShares

標普醫療保健服務 ETF - SPDR

醫療業 ETF - SPDR

醫療業 ETF - Vanguard

<p>摩根大通已將 HCA Healthcare 的目標股價從 535.00 美元下調至 490.00 美元，維持 “中性” 評級。該股票目前的共識評級為 “適度買入”，平均目標價格為 515.77 美元。HCA 的股票交易價格下跌至 405.77 美元，市值為 900.2 億美元。分析師預測本財年的每股收益為 30.07</p>

<p>HCA Healthcare (NYSE:HCA - Get Free Report) had its target price cut by research analysts at JPMorgan Chase &amp; Co. from $535.00 to $490.00 in a report issued on Tuesday,MarketScreener reports. The brokerage presently has a &#34;neutral&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price points to a potential upside of 20.76% from the stock's previous close.</p>
<div class="lb-trans"><p>HCA Healthcare（紐約證券交易所代碼：HCA - 獲取免費報告）在週二發佈的報告中，摩根大通將其目標價從 535.00 美元下調至 490.00 美元，MarketScreener 報道。該券商目前對該股票給予 “中性” 評級。摩根大通的目標價意味着該股票相較於之前的收盤價有 20.76% 的潛在上漲空間。</p>
</div><p>Get <strong>HCA Healthcare</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>HCA Healthcare</strong> 的提醒：</p>
</div><ul>
<li>The Aging of America Could Make HCA Healthcare a Long-Term Winner</li>
</ul>
<div class="lb-trans"><ul>
<li>美國老齡化可能使 HCA Healthcare 成為長期贏家</li>
</ul>
</div><p>A number of other research firms have also weighed in on HCA. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of HCA Healthcare in a research report on Wednesday, March 4th. The Goldman Sachs Group lifted their target price on shares of HCA Healthcare from $520.00 to $558.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, January 28th. Leerink Partners reduced their price objective on shares of HCA Healthcare from $573.00 to $500.00 and set an &#34;outperform&#34; rating for the company in a research report on Monday, April 27th. Wall Street Zen downgraded HCA Healthcare from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, May 2nd. Finally, KeyCorp dropped their price objective on HCA Healthcare from $550.00 to $510.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, April 27th. Sixteen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $515.77.</p>
<div class="lb-trans"><p>其他一些研究公司也對 HCA 發表了看法。Cantor Fitzgerald 在 3 月 4 日的研究報告中重申了對 HCA Healthcare 股票的 “增持” 評級。高盛集團在 1 月 28 日的報告中將 HCA Healthcare 的目標價從 520.00 美元上調至 558.00 美元，並給予該公司 “買入” 評級。Leerink Partners 在 4 月 27 日的研究報告中將 HCA Healthcare 的目標價從 573.00 美元下調至 500.00 美元，並對該公司給予 “跑贏大盤” 評級。華爾街 Zen 在 5 月 2 日的研究報告中將 HCA Healthcare 的評級從 “買入” 下調至 “持有”。最後，KeyCorp 在 4 月 27 日的報告中將 HCA Healthcare 的目標價從 550.00 美元下調至 510.00 美元，並對該股票給予 “增持” 評級。十六位研究分析師對該股票給予 “買入” 評級，七位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 515.77 美元。</p>
</div><p><strong>View Our Latest Report on HCA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 HCA 的最新報告</strong></p>
</div><h2>HCA Healthcare Stock Performance</h2>
<div class="lb-trans"><h2>HCA Healthcare 股票表現</h2>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>該 ETF 證明醫療保健反彈是真實的</li>
</ul>
</div><p>NYSE HCA traded down $17.02 during trading on Tuesday, reaching $405.77. The company's stock had a trading volume of 245,089 shares, compared to its average volume of 1,122,558. HCA Healthcare has a twelve month low of $330.00 and a twelve month high of $556.52. The firm has a market cap of $90.02 billion, a price-to-earnings ratio of 14.04, a P/E/G ratio of 1.34 and a beta of 1.18. The business's fifty day moving average price is $476.49 and its 200-day moving average price is $485.66.</p>
<div class="lb-trans"><p>週二，紐約證券交易所 HCA 的交易價格下跌 17.02 美元，達到 405.77 美元。該公司的股票交易量為 245,089 股，而其平均交易量為 1,122,558 股。HCA Healthcare 的十二個月低點為 330.00 美元，十二個月高點為 556.52 美元。該公司的市值為 900.2 億美元，市盈率為 14.04，市盈率/增長比率為 1.34，貝塔值為 1.18。該公司的 50 日移動平均價格為 476.49 美元，200 日移動平均價格為 485.66 美元。</p>
</div><p>HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings results on Friday, April 24th. The company reported $7.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.19 by ($0.04). The company had revenue of $19.11 billion during the quarter, compared to analyst estimates of $19.09 billion. HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The business's revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $6.45 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, sell-side analysts forecast that HCA Healthcare will post 30.07 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>HCA Healthcare（紐約證券交易所代碼：HCA - 獲取免費報告）最近在 4 月 24 日發佈了季度財報。該公司報告每股收益（EPS）為 7.15 美元，低於共識預期的 7.19 美元（差額為 0.04 美元）。該公司在本季度的收入為 191.1 億美元，而分析師預期為 190.9 億美元。HCA Healthcare 的淨利潤率為 8.89%，股本回報率為負 295.93%。該公司的收入同比增長 4.3%。去年同期，該公司每股收益為 6.45 美元。HCA Healthcare 已將其 2026 財年的指導目標設定為 29.100-31.500 美元每股收益。作為一個整體，賣方分析師預測 HCA Healthcare 在當前財年將發佈 30.07 美元每股收益。</p>
</div><h2>Insider Buying and Selling at HCA Healthcare</h2>
<div class="lb-trans"><h2>HCA Healthcare 的內部買賣</h2>
</div><ul>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 07/28 - 08/01</li>
</ul>
</div><p>In related news, EVP Michael R. Mcalevey sold 1,694 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $533.37, for a total value of $903,528.78. Following the sale, the executive vice president owned 8,853 shares of the company's stock, valued at approximately $4,721,924.61. This represents a 16.06% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Michael R. Mcalevey 在 2 月 18 日的交易中出售了 1,694 股公司的股票。該股票以平均價格 533.37 美元出售，總價值為 903,528.78 美元。出售後，該執行副總裁持有 8,853 股公司的股票，價值約為 4,721,924.61 美元。這代表其持股減少了 16.06%。該交易已在證券交易委員會的備案中披露，可以通過此鏈接訪問。公司內部人士目前持有 1.50% 的股票。</p>
</div><h2>Institutional Trading of HCA Healthcare</h2>
<div class="lb-trans"><h2>HCA Healthcare 的機構交易</h2>
</div><p>Large investors have recently made changes to their positions in the stock. National Pension Service increased its stake in HCA Healthcare by 2.9% in the third quarter. National Pension Service now owns 626,585 shares of the company's stock valued at $267,051,000 after purchasing an additional 17,531 shares during the last quarter. Savant Capital LLC increased its stake in shares of HCA Healthcare by 37.7% during the 3rd quarter. Savant Capital LLC now owns 4,548 shares of the company's stock valued at $1,938,000 after acquiring an additional 1,246 shares during the last quarter. Sector Gamma AS boosted its position in shares of HCA Healthcare by 36.0% in the third quarter. Sector Gamma AS now owns 10,883 shares of the company's stock worth $4,638,000 after acquiring an additional 2,883 shares during the last quarter. Nordea Investment Management AB increased its position in HCA Healthcare by 11.2% during the fourth quarter. Nordea Investment Management AB now owns 1,084,590 shares of the company's stock worth $507,393,000 after purchasing an additional 108,849 shares during the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of HCA Healthcare by 2,855.2% in the 3rd quarter. AlphaQuest LLC now owns 5,999 shares of the company's stock valued at $2,557,000 after purchasing an additional 5,796 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近對該股票的持倉進行了調整。國家養老服務在第三季度將其在 HCA Healthcare 的股份增加了 2.9%。國家養老服務目前持有 626,585 股公司股票，價值為 267,051,000 美元，此前在上個季度購買了 17,531 股。Savant Capital LLC 在第三季度將其在 HCA Healthcare 的股份增加了 37.7%。Savant Capital LLC 目前持有 4,548 股公司股票，價值為 1,938,000 美元，此前在上個季度增加了 1,246 股。Sector Gamma AS 在第三季度將其在 HCA Healthcare 的持倉增加了 36.0%。Sector Gamma AS 目前持有 10,883 股公司股票，價值為 4,638,000 美元，此前在上個季度增加了 2,883 股。Nordea Investment Management AB 在第四季度將其在 HCA Healthcare 的持倉增加了 11.2%。Nordea Investment Management AB 目前持有 1,084,590 股公司股票，價值為 507,393,000 美元，此前在上個季度購買了 108,849 股。最後，AlphaQuest LLC 在第三季度將其在 HCA Healthcare 的持倉增加了 2,855.2%。AlphaQuest LLC 目前持有 5,999 股公司股票，價值為 2,557,000 美元，此前在上個季度增加了 5,796 股。機構投資者和對沖基金持有該公司 62.73% 的股票。</p>
</div><h2>About HCA Healthcare</h2>
<div class="lb-trans"><h2>關於 HCA Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.</p>
<div class="lb-trans"><p>HCA Healthcare 是一家以盈利為目的的醫療設施運營商，總部位於田納西州納什維爾。該公司成立於 1968 年，擁有並運營一系列醫院和相關醫療設施，並通過有機擴展和收購成長為大型住院和門診服務提供商。</p>
</div><p>The company's core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA's services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.</p>
<div class="lb-trans"><p>該公司的核心業務包括急性護理醫院、獨立外科和急救中心以及門診診所的運營。HCA 的服務涵蓋住院護理、外科服務、急救醫學、診斷影像和實驗室檢測，以及各種門診和流動護理服務。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than HCA Healthcare</li>
<li>Rewiring AI: NextEra Energy Sparks a Mega Merger</li>
<li>Flipping the Switch: Is Ford the Next Big Energy Stock?</li>
<li>Does Nano Nuclear Energy’s New Deal Amp the Outlook?</li>
<li>3 Dividend Stocks With Insiders Buying in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 HCA Healthcare 更好</li>
<li>重塑人工智能：NextEra Energy 引發了一場巨型合併</li>
<li>切換開關：福特會是下一個大能源股票嗎？</li>
<li>納米核能的新交易是否提升了前景？</li>
<li>3 只內部人士在 2026 年買入的股息股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhDQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=HCA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in HCA Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 HCA Healthcare 嗎？</h2>
</div><p>Before you consider HCA Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 HCA Healthcare 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 HCA Healthcare 並不在名單上。</p>
</div><p>While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 HCA Healthcare 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

Market Beat

摩根大通

高盛

科凱國際

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

摩根大通的分析師將 HCA Healthcare（NYSE:HCA）的目標股價下調至 490.00 美元